Aleksander Krag on the utility of PEth for subclassifying individuals at risk of steatotic liver disease
From The Lancet Gastroenterology & Hepatology in conversation with by The Lancet Group
February 23, 2026 · 20 min
About this episode
Aleksander Krag discusses the use of PEth as a biomarker for subclassifying individuals at risk of steatotic liver disease.
Steatotic liver disease labels hinge on alcohol intake, but self-report is often inaccurate. In this episode, Aleksander Krag (Odense University Hospital) discusses a large Danish study using phosphatidylethanol (PEth), a direct blood biomarker of recent drinking, showing substantial underestimation and potential reclassification from MASLD to MetALD/ALD. Click here to read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00187-6/fulltext Medical imaging an...
People in this episode
Guest: Aleksander Krag
Topics covered
- steatotic liver disease
- alcohol intake
- biomarkers
- health research
- medical imaging
Keywords
- steatotic liver disease
- PEth
- alcohol consumption
- biomarker
- Danish study
Mentioned in this episode
Organizations: Odense University Hospital, The Lancet
Books & works: phosphatidylethanol (PEth)
Explore listener stats, chart rankings, contacts and more on the The Lancet Gastroenterology & Hepatology in conversation with podcast page.